<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00057707</url>
  </required_header>
  <id_info>
    <org_study_id>030143</org_study_id>
    <secondary_id>03-M-0143</secondary_id>
    <nct_id>NCT00057707</nct_id>
  </id_info>
  <brief_title>Effects of Modafinil on Brain Function in Patients With Schizophrenia</brief_title>
  <official_title>Randomized, Double-Blinded, Placebo Controlled Study of the Effects of Modafinil on Cognitive Function in Patients With Schizophrenia and Normal Controls Based on COMT Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate whether modafinil improves cognition in patients with schizophrenia&#xD;
      and healthy volunteers. Modafinil is a drug that has been FDA approved for day-time&#xD;
      sleepiness and allegedly increase the amount of the neurotransmitter dopamine in the frontal&#xD;
      cortex of the brain&#xD;
&#xD;
      ...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psychopharmacological modulation of the catecholaminergic system can enhance some aspects of&#xD;
      cognitive function. For example, COMT inhibitors can slightly improve working&#xD;
      memory/executive function. Similarly, modafinil, a catecholaminergic agonist that increases&#xD;
      extracellular dopamine in the prefrontal cortex was also shown to improve delay-dependent&#xD;
      working memory. Differences in the response between individuals might be related to a number&#xD;
      of factors, including variations in the genes. The recent finding that a polymorphism in the&#xD;
      catechol-o-methyl-transferase (COMT) gene, which produces a 4 fold change in enzyme activity,&#xD;
      accounts for 4% of the variance in performance of working memory tasks in humans suggest that&#xD;
      COMT genotype may predict response to COMT inhibitors or to other agonists that increase&#xD;
      catecholaminergic function in the frontal cortex.&#xD;
&#xD;
      In the present investigation our goal is to examine, in normal controls and patients with&#xD;
      schizophrenia, the effect of modafinil, a drug that increases DA output in the frontal&#xD;
      cortex, on cognitive function and brain physiology. We predict that both normal controls and&#xD;
      patients with schizophrenia with the val/val genotype will have a significant improvement in&#xD;
      working memory compared with individuals possessing other genotypes. Furthermore, in&#xD;
      conjunction with other NIMH imaging protocols, we predict that modafinil will produce a&#xD;
      similar genotype-dependent effect on the neurophysiological correlates related to working&#xD;
      memory assayed with fMRI. The present protocol will provide new insights on the importance of&#xD;
      this genetic polymorphism in the regulation of aminergic-controlled cognitive function in&#xD;
      normal individuals. Furthermore, this protocol will test whether modafinil offers a new&#xD;
      treatment -based on genotype - for cognitive impairment in schizophrenia. The FDA granted a&#xD;
      waiver for the use of Modafinil in this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 26, 2003</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Genetic differences in working memory testing or fMRI activation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Panss, Ham-A, Blood draws for drug levels and liver enzymes</measure>
  </secondary_outcome>
  <enrollment type="Actual">176</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Functional MRI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neuropsychological Testing</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Prior participation under NIH protocol # 95-M-0150, or new normal volunteers. Patients with&#xD;
        Schizophrenia or Schizoaffective disorder that meet criteria for NIH protocol # 95-M-0150&#xD;
        will be included.&#xD;
&#xD;
        No active Axis I or Axis II diagnosis in normal volunteers.&#xD;
&#xD;
        Age range: 18-50 years.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Subjects with a history of cardiovascular disease, liver disease and other medical&#xD;
        illnesses, current active substance abuse or history of substance abuse for more than 5&#xD;
        years, and untreated or uncontrolled hypertension will be excluded. Individuals with&#xD;
        persistent tardive dyskinesia will be excluded from the study. An electrocardiogram, blood&#xD;
        pressure, pulse rate and metabolic panel including LFTs will be checked on all subjects&#xD;
        prior to participation in the study.&#xD;
&#xD;
        Schizophrenic patients taking, a COMT inhibitor, buproprion, stimulants, other cognitive&#xD;
        enhancers or any illicit drugs of abuse, or MAO inhibitors will be excluded.&#xD;
&#xD;
        Normal control subjects taking any medications affecting brain function will be excluded.&#xD;
&#xD;
        Pregnant or breastfeeding women. Women of childbearing potential will undergo a urine&#xD;
        pregnancy test the day the study initiates and screened by history for the possibility of&#xD;
        pregnancy.&#xD;
&#xD;
        Patients with significant history of violence against self or others as established in&#xD;
        protocol # 89-M-0160 (Inpatient Evaluation of Neuropsychiatric Patients)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose A Apud, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Aguirre JA, Cintra A, Hillion J, Narv√°ez JA, Jansson A, Antonelli T, Ferraro L, Rambert FA, Fuxe K. A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci Lett. 1999 Nov 19;275(3):215-8.</citation>
    <PMID>10580713</PMID>
  </reference>
  <reference>
    <citation>Aksoy S, Klener J, Weinshilboum RM. Catechol O-methyltransferase pharmacogenetics: photoaffinity labelling and western blot analysis of human liver samples. Pharmacogenetics. 1993 Apr;3(2):116-22.</citation>
    <PMID>8518836</PMID>
  </reference>
  <reference>
    <citation>Andreasen NC, Arndt S, Cizadlo T, O'Leary DS, Watkins GL, Ponto LL, Hichwa RD. Sample size and statistical power in [15O]H2O studies of human cognition. J Cereb Blood Flow Metab. 1996 Sep;16(5):804-16.</citation>
    <PMID>8784225</PMID>
  </reference>
  <verification_date>June 16, 2017</verification_date>
  <study_first_submitted>April 5, 2003</study_first_submitted>
  <study_first_submitted_qc>April 4, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2003</study_first_posted>
  <last_update_submitted>December 6, 2019</last_update_submitted>
  <last_update_submitted_qc>December 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2019</last_update_posted>
  <keyword>Catecholamines</keyword>
  <keyword>Dopamine</keyword>
  <keyword>fMRI</keyword>
  <keyword>Working Memory</keyword>
  <keyword>Clinical Trial</keyword>
  <keyword>Stabilization</keyword>
  <keyword>Inpatients</keyword>
  <keyword>Placebo</keyword>
  <keyword>Modafinil</keyword>
  <keyword>Normal Volunteers</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Healthy Volunteer</keyword>
  <keyword>HV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

